Home News Johnson & Johnson Underperforms Ahead of Q4-22 Earnings Report

Johnson & Johnson Underperforms Ahead of Q4-22 Earnings Report


Johnson & Johnson is a stock that naturally attracts a lot of investor interest because it is a component of the S&P 500 and one of the 30 stocks that make up the Dow Jones Industrial Index.

J&J’s rebound from 159.11 Some of the losses that were suffered in April 2022 were recouped, but the recovery process stalled. 181.02 In December. Although there was an attempt to match December’s high in January, it was only recorded so far as 180.88Before you go beyond the 174.06 support. It trades in the range of ±168.00.

Johnson & Johnson stock has declined more than 6% These two weeks have been quite busy. Information circulating suggests that Covid-19 production has been cut by the company, which is behind Moderna and Pfizer. These issues aside, it is unlikely investors will panic sell the stock at $443 billion with institutional quality.

Johnson&Johnson will report earnings before the market open and hold a conference call on Tuesday 24th January. Analysts anticipate single-digit earnings growth for Johnson&Johnson. Although the company saw strong sales in the pharmaceuticals segment, which exceeded expectations, this quarter could be affected by Covid-related…

Continue reading…

Previous articleGlobal Flash PMIs and Return of Investor Optimism
Next articleFinalto appoints Klelia Orphanidou B2B Head for Regulatory Compliance